Non-Communicable Respiratory Disease and Air Pollution Exposure in Malawi (CAPS): A Cross-Sectional Study

#Rebecca Nightingale (MRes)1,2, #Maia Lesosky (PhD)3, Graham Flitz (MS)4, Sarah J. Rylance (MRes)1,2, Jamilah Meghji (MPH)1,2, Peter Burney (MD)5, #John Balmes (MD)4,6, #Kevin Mortimer (PhD)1,2

1Liverpool School of Tropical Medicine, Liverpool, UK; 2Malawi Liverpool Wellcome Trust Programme, Blantyre, Malawi; 3Division of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town; 4University of California, Berkeley, USA; 5National Heart and Lung Institute, Imperial College, London, UK; 6University of California, San Francisco, CA, USA.

# joint first authors; * joint senior authors
*Corresponding author: Kevin.mortimer@lstmed.ac.uk; 00447708510482

DESCRIPTIVE CODE AND WORD COUNTS
Descriptive code: 6.1
Abstract word count: 250
Manuscript word count: 3517

AUTHOR CONTRIBUTIONS
Design: KM, PB, JB
Acquisition of data: RN, KM, PB, JB
Analysis of data: RN, ML, GF, SR
Interpretation of data: RN, ML, GF, SR, JM, PB, JB, KM
Writing the manuscript, approval of the version to be published and agreement to be accountable for all aspects of the work: All authors

FUNDING
This work was funded by a New Investigator Research Grant from the Medical Research Council (Ref: MR/L002515/1), a Joint Global Health Trials Grant from the Medical Research Council, UK Department for International Development and Wellcome Trust (Ref: MR/K006533/1), a US National Institutes of Health R56 Grant (Ref: R56ES023566) and a Wellcome Trust grant (085790/Z/08/Z).

RUNNING HEAD
NCD-Respiratory in Malawi.

ASSOCIATED FUNDING
Additional support was provided by the NIHR Global Health Research Unit on Lung Health and TB in Africa at LSTM - “IMPALA”. In relation to IMPALA (grant number 16/136/35) specifically: IMPALA was commissioned by the National Institute of Health Research using Official Development Assistance (ODA) funding. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health.

IMPACT
The characteristics of non-communicable respiratory diseases in sub-Saharan Africa may be different to previously thought with more spirometric restriction and less obstruction including household air pollution-associated COPD. There is a need for clinically- and cost-effective
approaches for the prevention and control of non-communicable respiratory diseases in sub-Saharan Africa.

**AT A GLANCE:**

**Scientific knowledge**
Non-communicable respiratory diseases and exposure to air pollution are thought to be important causes of morbidity and mortality in sub-Saharan African adults. Recent Burden of Obstructive Lung Disease (BOLD) studies found a high burden of spirometric restriction but little spirometric obstruction in several sub-Saharan African countries and no association between spirometric obstruction and use of dirty-burning fuels. It is not known whether an association between spirometric obstruction and solid fuel use would be seen if personal exposure to air pollution were measured in addition to self-reported exposure. The Cooking And Pneumonia Study (CAPS) – a trial of cleaner burning biomass-fueled cookstoves on pneumonia in children under the age of five in rural Malawi – offered the opportunity to explore this and other secondary trial outcomes in adults.

**What this study adds:**
In adults living in Chikhwawa, rural Malawi: 13·6% of participants had chronic respiratory symptoms (mainly cough); over 40% had abnormal spirometry (mainly spirometric restriction); day-to-day air pollution exposures were approximately three times the World Health Organization upper safety limit; air pollution exposures were not associated with demographic, clinical or spirometric characteristics; and there was no association between CAPS trial arm and any of the secondary trial outcomes.
Background

Non-communicable respiratory diseases and exposure to air pollution are thought to be important contributors to morbidity and mortality in sub-Saharan African adults.

Methods

We did a cross-sectional study among adults in communities participating in a randomised controlled trial of a cleaner-burning biomass-fuelled cookstove intervention (CAPS) in rural Malawi. We assessed chronic respiratory symptoms, spirometric abnormalities, personal exposure to air pollution (fine particulate matter (PM$_{2.5}$) and carbon monoxide (CO)). Weighted prevalence estimates were calculated; multivariable and intention-to-treat analyses were done.

Results

1481 participants (mean (SD)) age 43·8 (17·8) 57% female) were recruited. The prevalence of chronic respiratory symptoms, spirometric obstruction and restriction were 13·6% (95% CI:11.9-15.4), 8·7% (95% CI:7·0-10·7) and 34·8% (95% CI:31·7-38·0), respectively. Median 48-hour personal PM$_{2.5}$ and CO exposures were 71·0 µg/m$^3$ (IQR:44-6-119·2) and 1·23 ppm (IQR:0·79-1·93), respectively. Chronic respiratory symptoms were associated with current/ex-smoking (OR=1·59 (95% CI:1·05-2·39)), previous TB (OR=2·50 (95% CI:1·04-15·58)) and CO exposure (OR=1·46 (95% CI:1·04-2·05)). Exposure to PM$_{2.5}$ was not associated with any demographic, clinical or spirometric characteristics. There was no effect of the CAPS intervention on any of the secondary trial outcomes.

Conclusion

The burden of chronic respiratory symptoms, abnormal spirometry and air pollution exposures in adults in rural Malawi is of considerable potential public health importance. We found little evidence that air pollution exposures were associated with chronic respiratory symptoms or spirometric abnormalities and no evidence that the CAPS intervention had
effects on the secondary trial outcomes. More effective prevention and control strategies for non-communicable respiratory disease in sub-Saharan Africa are needed.
INTRODUCTION

Highly polluting fuels including animal dung, crop residues, wood, charcoal and kerosene are used by almost half the world’s population to provide energy for cooking, heating and lighting.\textsuperscript{1–3} These fuels are typically burned in and around the home environment in inefficient ways – e.g. open fires – which leads to high levels of air pollution in and immediately outside of homes. The World Health Organization (WHO) has estimated that exposure to household air pollution leads to over four million deaths each year.\textsuperscript{3} The latest Global Burden of Disease Study estimates this number is closer to 2.5 million but even these lower estimates represent a substantial burden of morbidity and mortality that falls particularly heavily on the world’s poor.\textsuperscript{4} Household air pollution has been considered to increase the risk of pneumonia in children and of chronic obstructive pulmonary disease (COPD) and cardiovascular disease in adults.\textsuperscript{1–3}

In 2017, we published the findings of a cluster-randomised controlled trial of introducing a cleaner-burning biomass-fuelled cookstove to prevent pneumonia in children under 5 years of age in rural Malawi (the Cooking and Pneumonia Study – CAPS).\textsuperscript{5} CAPS is one of a small number of trials done to date to evaluate the effects of reducing biomass smoke exposure on health outcomes and is the largest trial of a cookstove intervention on health outcomes conducted anywhere in the world (n=10,750 children from 8,626 households across 150 clusters). The major finding of this trial was that there was no difference between the intervention and control groups among children in pneumonia incidence defined using the criteria of the Integrated Management of Childhood Illness (IMCI) programme. This unexpected finding has cast some doubt on the assumptions made by the Global Alliance for Clean Cookstoves (GACC) that cleaner cookstoves and fuels save lives.\textsuperscript{6–11}

In this paper we report the findings of a cross-sectional study of the prevalence and determinants of non-communicable respiratory disease among adults living in communities
that participated in CAPS which addresses the pre-specified secondary trial objective of determining prevalence and determinants of obstructive lung disease in adults in rural Malawi.5 In this setting, use of highly polluting fuels for day-to-day household energy requirements is the norm and therefore a high burden of COPD associated with household air pollution was expected.

METHODS

Study design
We did a cross-sectional study of the prevalence and determinants of non-communicable respiratory disease among adults living in Chikhwawa District, Malawi.

Setting
Chikhwawa is approximately 50 kilometres from the nearest city, Blantyre, on the southern Shire River Valley, and consists primarily of subsistence farmers living in rural village communities. The Malawi College of Medicine Research Ethics Committee (ethics committee reference number P.11/12/1308) and the Liverpool School of Tropical Medicine Research Ethics Committee (ethics committee reference number 12.40) approved the CAPS trial protocol that includes this work, a summary of which was published by The Lancet.12 Study registration: ISRCTN 59448623.

Participants
Following community engagement events that included village leaders and other community representatives, a list of all the adults living in each of the 50 villages participating in CAPS in Chikhwawa was obtained from local community health workers known as Health Surveillance Assistants. These lists were collated and used by an independent statistician at
the BOLD centre in London to obtain a population-representative sample of adults over the age of 18 with stratification by age and gender. All potential participants sampled in this way were then individually invited to participate with written informed consent (or witnesses thumbprint for those unable to read and write) obtained from those who agreed. People who were acutely unwell, not permanent residents or pregnant were excluded.

**Procedures**

Fieldworkers who had undergone study-specific training and met the required quality standards did home visits according to standardised operating procedures. With the exception of the air pollution monitoring procedures which are not part of the BOLD study protocol, all procedures were conducted in accordance with the BOLD study protocol which has been described previously. Minimal demographic information was collected from participants who declined to participate in the full study. Fieldworkers administered BOLD study questionnaires in the local language, Chichewa. Height and weight were measured using a portable stadiometer and scales. All eligible participants were asked to do pre- and post-bronchodilator spirometry which BOLD centre certified fieldworkers performed to European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines using the ndd EasyOne Spirometer (ndd Medical Technologies; Zurich, Switzerland). Up to three repeat visits were arranged to achieve the required spirometry quality standards. Spirometry data were sent electronically to the BOLD centre for quality control.

Personal exposures to fine particulate matter (PM$_{2.5}$) and carbon monoxide (CO) were measured continuously for 48 hours using the Indoor Air Pollution (IAP) 5000 Series Monitor (Aprovecho Research Center, Oregon, USA). The IAP 5000 sampled air from the breathing zone using a short tube and logged continuous PM$_{2.5}$ and CO using a light-scattering photometer and an electrochemical cell CO sensor, respectively. All monitors were calibrated at the Aprovecho Research Center prior to use in the study. Monitors were worn in small backpacks apart from during sleep when they were kept beside the sleeping mat or bed.
Variables

Clinical outcomes were presence or absence of specific symptoms as assessed by questionnaire. The questions (outcomes) asked were as follows: Do you usually have a cough when you don’t have a cold (cough outcome)? Do you usually bring up phlegm from your chest (phlegm outcome)? Have you had wheezing/whistling in your chest at any point in the 12 months, in the absence of a cold (wheeze outcome)? Do you have shortness of breath when hurrying on the level or walking up a slight hill (dyspnoea outcome)? And have your breathing problems interfered with your daily activities (functional limitation outcome)? A composite variable for any symptoms was created by defining as positive if an individual reported any of the above symptoms (any symptoms outcome).

Continuous FEV$_1$ and FVC spirometry values were used in the primary analysis. Spirometric obstruction and restriction were defined according to the NHANES III Caucasian reference range lower limits of normal.$^{15}$

Exposures of interest included personal exposure to PM$_{2.5}$ or CO as measured by the personal monitoring device, and two exposures assessed by questionnaire: smoking status and previous episode of TB. A questionnaire assessed variable asking for any biomass exposure was considered, but as the majority (>99%) indicated yes, it was not included in any modelling.

Raw PM$_{2.5}$ and CO exposures were corrected for background levels using calibration values for each monitoring period. In cases where calibration data were missing or corrupted (<5%), aggregated mean calibration values were used. Observations where less than 2000 min of time were recorded were excluded, as were monitoring periods affected by device malfunction. Both PM$_{2.5}$ and CO were log$_{10}$ transformed for presentation and inclusion in models due to large positive skew.
Potential confounders/effect modifiers included were Body Mass Index (BMI), and/or height (cm) and weight (kg) variables, as well as age, years of education, and sex.

**Study size**

We initially invited 2000 people to participate but increased this to 3000 to achieve the required sample size. Participants were stratified into two age groups: 18-39 years and 40 years or above. We estimated that, after allowing for unequal age and gender distributions, refusals and inability to provide spirometry measurements of acceptable quality, a sample of just 300 participants in any one gender / age stratum (1200 total) would provide an estimate of chronic airflow limitation prevalence in this stratum with a precision (95% CI) of ±3·3 to ±5·0% assuming a prevalence of 10 to 25%.

**Statistical methods**

Univariate analysis was completed using descriptive statistics to explore the characteristics of the study population. Descriptive analysis is presented for clarity using categorical versions of BMI (underweight, normal, overweight or obese) and categorical versions of age, however age, weight and height were entered into models as continuous variables. Participants who completed the study in full or in part were assessed for selection bias using the chi-square and Student’s t-test. Multivariable logistic regression was used to estimate the strength of the association between measured exposure variables and dichotomous clinical outcomes, adjusting for potential confounders. All models were adjusted for age, sex, weight, and height. Linear multivariable regression was used to estimate the association between exposures and continuous lung function values (FEV₁, FVC, FEV₁/FVC). Secondary exploratory trial efficacy analyses were by intention-to-treat (ITT). Statistical significance was nominally set at alpha = 0·05. Stata version 14.2 and R version 3.4 statistical software was used for data analysis (Stata Statistical Software: R.14; StataCorp LLC, College Station, TX).
Role of the funding source

The funders had no role in the study design, data collection, analysis, interpretation or writing of the report. The corresponding author had full access to all the study data and had final responsibility for the decision to submit for publication.

RESULTS

Between August 2014 and July 2015, we attempted to contact the 3000 adults sampled to invite them to participate of whom 1481 (49.4%) consented and completed BOLD study questionnaires. Of these, 950 (64.6%) went on to do spirometry; the remaining 520 (35.3%) were unable to do spirometry because they could not physically co-operate with the procedure (n=258; 48.9%), had a fieldworker-determined contra-indication (n=193; 37%) or refused (n=69; 13.3%). Of the 1481 participants, 1144 (77.2%) underwent personal air pollution exposure monitoring. There were 424 (28.6%) participants from CAPS intervention or control households (Figure 1).

The mean age (SD) of participants was 43.8 (17.8) years and 57% were female (Table 1). Just over half the participants had been educated only to primary school level with a third having had no formal school education. The use of biomass fuels for cooking was almost universal (99.8%).

One or more chronic respiratory symptom was reported by 201 (13.6% (95% CI 11.9 - 15.4)) participants (Table 1 and Figure 2). Respiratory symptoms were more commonly reported with increasing age. Regular cough was reported by 11.1% (95% CI 9.6 - 12.8) while 2.6% (95% CI 1.9 - 3.5) reported usually coughing up phlegm. Breathlessness and wheeze were less commonly reported: 1.6% (95% CI 1.0 - 2.3) and 1.6% (95% CI 1.0 - 2.3), respectively. Respiratory symptoms that limited functional ability were reported by 2.9% (95% CI 2.2 -
A previous diagnosis of TB was reported by 3·2% (95% CI 2·4 - 4·2) which was more common with increasing age. Current or former smoking was reported by 22·1% (95% CI 20·1 - 24·3) although only 4·3% had greater than a 10 pack-year history. Many participants (14·4%) had a low BMI.

Of the 950 participants who did spirometry, 886 (93·2%) achieved BOLD study quality standards and were included in the analyses. Factors associated with declining or not completing spirometry to ERS/ATS standards were: older mean age [48 vs. 39 years (p<0·001)]; being female [65% vs. 51% (p<0·001)]; lower mean years of education [2 vs. 5 years (p<0·001)]; lower mean BMI [20·7 vs. 21·3 (p<0·001)]. As shown in Table E1 in the Online Data Supplement, participants who completed spirometry were less likely to have cough, wheeze and dyspnoea compared to those who didn’t complete spirometry and were slightly more likely to have phlegm and functional limitation although none of these differences were statistically significant. Spirometric obstruction and restriction were present in 8·7% (95% CI: 7·0 - 10·7) and 34·8% (95% CI: 31·7 - 38·0) of the 886 participants that met the required quality standards, respectively.

Of the 1144 participants (mean age (SD) 43.9 (17.9) years; 57% female) who underwent personal exposure monitoring, 1117 (97·6%) had valid exposure monitoring records. The 48-hour median personal PM$_{2.5}$ and CO exposures were 71·0 µg/m$^3$ (IQR: 44·6 - 119·2) and 1·23 ppm (IQR: 0·79 - 1·93), respectively. There was weak correlation between these two air pollution exposure measures (Figure 3).

In logistic multivariable analysis, smoking (OR=1·56 (95% CI: 1·01 - 2·41)) and previous TB (OR=2·81 (95% CI: 1·19 - 6·08) were associated with cough (Table 2 and Table E1 in the Online Data Supplement). In continuous multivariable analysis, both FEV$_1$ and FVC had a negative association with increasing age and were higher for men compared to women (Table 3). Smoking (coefficient estimate = -0·09 (95% CI: -0·16 - -0·01) and previous TB
(coefficient estimate = -0.46 (95% CI: -0.64 - -0.28)) were associated with FEV1 and previous TB was associated with FVC (coefficient estimate = -0.35 (95% CI: -0.56 - -0.15)). There was no association between personal exposure to PM<sub>2.5</sub> and any of the demographic and clinical characteristics or spirometric indices (Tables 4 and 5). The only statistically significant association was between exposure to CO and reporting “any chronic respiratory symptoms” (OR = 1.46 (95% CI: 1.04 - 2.05)). There were no statistically significant associations between personal exposure to CO and any other demographic and clinical characteristics or to any spirometric indices. There were 424 (227 intervention; 197 control) participants in the CAPS ITT population, however not all of them had complete spirometry (133 without) or exposure measures (87 without). There were no differences in respiratory symptoms, spirometric indices or exposure to CO or PM<sub>2.5</sub> between the intervention and control groups (Table 6).

**DISCUSSION**

The main findings of this cross-sectional study of the burden and determinants of non-communicable respiratory disease in adults living in Chikhwawa, rural Malawi were that: 13.6% of participants had chronic respiratory symptoms (mainly cough); over 40% had abnormal spirometry (mainly spirometric restriction); day-to-day air pollution exposures were approximately three times the WHO upper safety limit; and there was no association between CAPS trial arm and any of the secondary trial outcomes in the subset of adults included both in this study and the trial.

The finding of a low prevalence of spirometric obstruction in this setting - where highly polluting fuels are almost universally used for household energy needs and where exposure to household air pollution is high – is surprising given that household air pollution-associated COPD has been suggested to be a major global health problem and as such would be expected to be highly prevalent in our study setting. This finding is consistent with an
emerging body of evidence challenging the dogma that exposure to household air pollution is a major cause of COPD including a recent pooled analysis of BOLD Study data from low-, middle- and high-income countries. This analysis found no association between spirometric obstruction and self-reported use of solid fuels for cooking or heating. This is, however, an area of controversy with investigators disagreeing about the interpretation of the available data.

Many of the studies conducted to date looking at the association between COPD and exposure to household air pollution have had important methodological limitations including case definition and exposure assessments. So far, studies of the long-term effects of air pollution have had to use a self-reported history of exposure with all the limitations that this may imply. To improve exposure assessment, we included 48 hours of personal air pollution exposure measurements in study participants in addition to questionnaire-based exposure assessments. Whilst this approach and the particular devices used have their limitations, by doing this we were able to deliver the first study of the burden of non-communicable lung disease anywhere in the world to incorporate BOLD study methodology and measurements of personal air pollution exposure and to do so in almost 1000 participants.

Although personal air pollution exposure levels were undoubtedly high and at levels at which adverse health effects would be expected, and although widely considered a risk factor for non-communicable respiratory diseases and COPD in particular, the only respiratory outcome associated with measured exposure to PM$_{2.5}$ or CO was ‘any chronic respiratory symptoms’ with increased CO exposure. Interestingly, whether questionnaire-based or directly measured personal air pollution exposure assessments were used, there was no significant association between air pollution exposure and an increased risk of spirometric abnormalities. However, we acknowledge that 48-hour measurements of air pollutants may not be an adequate surrogate for cumulative exposure to household air pollution that has been associated, albeit by self-report, with COPD. Our observations, taken together with the
findings of other recent studies, bring into question the extent to which household air pollution and other sources of air pollution play in the development of abnormal lung function in rural African settings like this one in rural Malawi. It is plausible that the levels of personal exposure to air pollution seen are not high enough to accelerate lung function decline and the development of airflow obstruction in the way that tobacco smoke does; a prospective cohort study of the rate of decline in lung function in relation to air pollution exposures is needed in adults in sub-Saharan Africa to explore this further.

This study benefited from being conducted at the same time and in the same villages as CAPS which presented the opportunity to look for an effect of the CAPS intervention on respiratory symptoms, spirometric indices and personal air pollution exposures in a sub-sample of adults. Consistent with the main trial findings of no effect of the intervention on pneumonia in children under the age of 5, we found no evidence that the intervention was associated with beneficial effects on any of these trial secondary outcome measures amongst adults. However, these analyses were exploratory secondary analyses limited by a relatively small number of participants and therefore statistical power to detect effects and, whilst sufficient to see an effect on symptoms and air pollution exposures, there was limited time between intervention and outcome assessment for potential effects on spirometric indices to be seen. Other possible explanations for the lack of effect of the CAPS intervention on these outcomes include insufficient levels of intervention adoption, insufficient reductions in emissions and exposures, and other sources of air pollution exposure overwhelming any potential effect of the intervention.

A notable observation of this study was that 35% of participants had spirometric restriction when benchmarked against NHANES III Caucasian reference range values. We consider the approach we have taken of benchmarking against the NHANES III Caucasian reference ranges as the best we can do at this point in time whilst accepting that this and all other
currently available alternatives are not ideal. That includes locally-derived reference ranges that might be helpful in defining what is 'usual' lung function in asymptomatic non-smoking Malawian adults but which may be far from 'optimal potential normal lung function'. Since there is evidence that the prognostic significance of spirometric restriction holds irrespective of racial/ethnic group when benchmarked in this way, the finding of such a high burden of spirometric restriction in the rural Malawian population, and elsewhere in sub-Saharan Africa, is of considerable concern; observational cohort studies are needed to understand the clinical characteristics and prognostic significance of these findings. The underlying drivers of spirometric restriction in sub-Saharan African populations are not yet understood but we hypothesise that these are primarily environmental insults experienced in early life – e.g. malnutrition, infections and air pollution exposures pre-conception, in-utero and during childhood – such that adulthood is reached without maximal potential lung function having been achieved. Cross-sectional studies of the burden and determinants of non-communicable lung disease in children in sub-Saharan Africa are needed to explore whether the same patterns of abnormality are seen in early life and, if so, studies even earlier in the life course to identifying potential windows of opportunity to intervene to maximise lung health.

Strengths of this study include that it was conducted in a highly challenging research setting in one of the world’s poorest rural communities as part of the CAPS protocol; it is the first of the global BOLD studies to be conducted in a rural sub-Saharan African setting; and it is also the first BOLD study to incorporate personal air pollution exposure measurements and to do so at scale. Limitations include questionnaire assessments for most variables with potential for recall bias, the potential bias (e.g. under-estimation of the burden of spirometric abnormalities) caused by participants who did not do spirometry although the quality of those that did spirometry was generally high; and air pollution exposure assessments that provided only a 48-hour snapshot of exposure and were based on a light-scattering method alone for PM$_{2.5}$. 

In conclusion, we found that exposures to air pollution among Malawian adults living in communities participating in CAPS were at levels well beyond those considered safe by the WHO. In keeping with the primary outcome of the CAPS trial, we found no effect of the intervention on any of the secondary trial outcomes – respiratory symptoms, spirometric indices or air pollution exposures – in the sub-sample of adults participating in both this study and the trial. The prevalence of chronic respiratory symptoms and abnormal spirometry suggests that there may be an important burden of non-communicable respiratory disease in these communities. The characteristics of non-communicable respiratory disease in sub-Saharan Africa may be different to those previously expected with more spirometric restriction and less obstruction (and household air pollution-associated COPD) than has been thought to exist. There is a need to explore other plausible explanations for the poor lung function observed in these and other low- and middle-income country populations including further exploration of the role of tuberculosis, recurrent pneumonia, and nutrition. Clinically- and cost-effective approaches for the prevention and control of non-communicable respiratory diseases are very much needed in sub-Saharan Africa.

ACKNOWLEDGEMENTS
We thank the trial participants, village leaders and CAPS representatives, the study team in Chikhwawa, MLW and LSTM, the CAPS trial steering committee and data monitoring committee, the Malawi Ministry of Health, the Aprovecho Research Centre, the African Clean Energy (ACE) company and the BOLD Centre for their valued contributions to making this work a success. We thank Stephen Gordon for his comments on the paper.
REFERENCES

1. Gordon SB, Bruce NG, Grigg J et al. Respiratory risks form household air pollution in low and middle income countries. Lancet Respiratory Medicine 2014;2:823–860
2. Mortimer K, Gordon SB, Jindal SK, Accinelli RA, Balmes J, Martin WJ II. Household air pollution is a major avoidable risk factor for cardio-respiratory disease. Chest 2012;142(5):1308–15. doi: 10.1378/chest.12-1596
3. World Health Organization 2014. Indoor air quality guidelines: household fuel combustion. Available from: http://apps.who.int/iris/bitstream/10665/141496/1/9789241548885_eng.pdf
4. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390: 1345–422
5. Mortimer K, Ndamala CB, Naunje AW, Malava J, Katundu C, Weston W, Havens D, Pope D, Bruce NG, Nyirenda M, Wang D, Crampin A, Grigg J, Balmes J, Gordon SB. A cleaner burning biomass-fueled cookstove intervention to prevent pneumonia in children under 5 years old in rural Malawi (the Cooking and Pneumonia Study): a cluster randomised controlled trial. The Lancet 2017;389:167-175
6. www.cleancookstoves.org. Accessed October 2016
7. Ezzati M, Baumgartner JC. Household energy and health: where next for research and practice? The Lancet 2017;389:130-132
8. Miele CH, Checkley W. Clean Fuels to Reduce Household Air Pollution and Improve Health. Still Hoping to Answer Why and How. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1552-1554
9. Jones, R. The scale of the problem of obstructive lung disease in Africa becomes clearer, but where are the solutions? ERJ 2018 51: 1702562; DOI: 10.1183/13993003.02562-2017
10. Sood A, Assad NA, Barnes PJ, Churg A, Gordon SB, Harrod KS, Irshad H, Kurmi OP, Martin WJ 2nd, Meek P, Mortimer K, Noonan CW, Perez-Padilla R, Smith KR, Tesfaigzi Y, Ward T, Balmes J. ERS/ATS workshop report on respiratory health effects of household air pollution. Eur Respir J. 2018 Jan 4;51(1). pii: 1700698. doi: 10.1183/13993003.00698-2017.
11. Mortimer K, Balmes JB. Cookstove trials and tribulations: what is needed to decrease the burden of household air pollution? Ann Am Thor Soc 2018 Feb 21. doi: 10.1513/AnnalsATS.201710-331GH. [Epub ahead of print]
12. www.thelancet.com/protocol-reviews/13PRT-4689
13. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, Crapo RO, Jensen RL, Burney PG. The burden of obstructive lung disease initiative (BOLD): rationale and design. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2005;2(2):277-83.
14. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J 2005; 26:153-161
15. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187
16. Eisner MD, Anthonisen N, Coul tas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, Silverman EK, Balmes JR, Committee on Nonsmoking Copd E. Occupational Health A. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693-718
17. Kurmi OP, Semple S, Simkhada P, Smith WC, Ayres JG. COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. Thorax 2010; 65: 221-228
18. Hu G, Zhou Y, Tian J, Yao W, Li J, Li B, Ran P. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest 2010; 138: 20-31.
19. Po JY, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel
exposure in rural women and children: systematic review and meta-analysis. Thorax 2011; 66: 232-239
20. Amaral AF, Patel J, Kato BS, Obaseki DO, Lawin H, Tan WC, Juvekar SK, Harrabi I, Studnicka M, Wouters EF. Airflow Obstruction and Use of Solid Fuels for Cooking or Heating: BOLD Results. American Journal of Respiratory and Critical Care Medicine. 2018;197:595-610
21. Siddharthan T, Grigsby MR, Goodman D, Chowdhury M, Rubinstein A, Irazola V, et al. Association between household air pollution exposure and chronic obstructive pulmonary disease outcomes in 13 low- and middle-income country settings. Am J Respir Crit Care Med 2018;197:611–620
22. Balmes JR, Eisen EA. Household Air Pollution and Chronic Obstructive Pulmonary Disease. “A Riddle, Wrapped in a Mystery, Inside an Enigma”. American Journal of Respiratory and Critical Care Medicine 2018;197:547-549
23. Burney PG, Hooper R. Forced vital capacity, airway obstruction and survival in a general population sample from the USA. Thorax 2011; 66:49–54
24. Burney P, Jithoo A, Kato B, Janson C, Mannino D, Nizankowska-Mogilnicka E, Studnicka M, Tan W, Bateman E, Koçabas A, et al.; Burden of Obstructive Lung Disease (BOLD) Study. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. Thorax 2014;69:465–473
25. Meghji J, Nadeau G, Davis KJ, Wang D, Nyirenda MJ, Gordon SB, Mortimer K. Noncommunicable Lung Disease in Sub-Saharan Africa. A Community-based Cross-Sectional Study of Adults in Urban Malawi. American journal of respiratory and critical care medicine. 2016;194(1):67-76
26. Obaseki DO, Erhabor GE, Gnatiuc L, Adewole OO, Buist SA, Burney PG. Chronic airflow obstruction in a black African population: results of BOLD study, Ile-Ife, Nigeria. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2016;13(1):42-9
### Table 1: Demographic and clinical characteristics (n=1481)

| Characteristic         | Level                  | N (%)         |
|------------------------|------------------------|---------------|
| **Age group (yrs)**    |                        |               |
| <39                    | 686 (46.32)            |
| 40-49                  | 259 (17.49)            |
| 50-59                  | 216 (14.58)            |
| 60-69                  | 160 (10.80)            |
| >70                    | 160 (10.80)            |
| **Sex**                |                        |               |
| Male                   | 637 (43.01)            |
| Female                 | 844 (56.99)            |
| **Education**          |                        |               |
| None                   | 485 (32.79)            |
| Primary                | 758 (51.25)            |
| Middle                 | 205 (13.86)            |
| High school or College | 31 (2.10)              |
| Missing                | 2 (0.0)                |
| **Years of Education, mean (SD)** | 4.20 (4.09) |
| **Years education if any, mean (SD)** | 6.31 (3.44) |
| **Smoking**            |                        |               |
| Never smoker           | 1152 (77.8)            |
| Current or ever smoker | 328 (22.2)             |
| **Pack-years of smoking** |                      |
| 0                      | 1 152 (77.9)           |
| Up to 10 pack years   | 263 (17.8)             |
| >10 pack years        | 63 (4.3)               |
| Missing                | 3 (0.0)                |
| **BMI group, kg/m²**   |                        |               |
| Underweight (BMI<18.5) | 188 (14.4)             |
| Normal (BMI 18.5-25)   | 945 (72.5)             |
| Overweight (BMI 25-30) | 130 (10.0)             |
| Obese (BMI >30)        | 40 (3.1)               |
| Missing                | 178 (12.0)             |
| **Previous TB**        |                        |               |
| No                     | 1434 (92.3)            |
| Yes                    | 47 (3.2)               |
| **Symptoms**           |                        |               |
| Cough                  | 165 (11.1)             |
| Sputum                 | 38 (2.6)               |
| Wheeze                 | 23 (1.6)               |
| MRC dyspnoea II        | 23 (1.6)               |
| Any respiratory Symptoms | 201 (13.6)         |
| Functional limitation  | 43 (2.9)               |

Copyright © 2018 by the American Thoracic Society
### Table 2: OR (95% CI) for chronic respiratory symptom outcomes estimated by multivariable logistic regression

| Variable                  | Cough         | Phlegm** | Wheeze** | Dyspnoea** | Functional limitation | Any symptoms |
|---------------------------|---------------|-----------|-----------|-------------|----------------------|--------------|
| Age (years)               | 1.01          | 1.00      | 1.02      | 1.01        | 1.00                 | 1.00         |
|                          | (1.00, 1.02)  | (0.97, 1.02) | (0.99, 1.05) | (0.98, 1.04) | (0.95, 1.02) | (0.97, 1.02) |
| Male                      | ref           | ref       | ref       | ref         | ref                  | ref          |
| Female                    | 0.78          | 1.02      | 0.97      | 3.08        | 1.17                 | 1.08         |
|                          | (0.49, 1.25)  | (0.42, 2.51) | (0.30, 3.28) | (0.88, 11.65) | (0.28, 2.37) | (0.70, 1.67) |
| Never smoked              | ref           | ref       | ref       | ref         | ref                  | ref          |
| Ever smoked               | 1.56          | 1.37      | 0.77      | 1.85        | 0.65                 | 1.59         |
|                          | (1.01, 2.41)  | (0.58, 3.15) | (0.20, 2.47) | (0.51, 6.07) | (0.18, 1.93) | (1.05, 2.39) |
| Previous TB: No           | ref           | -         | -         | -           | ref                  | ref          |
| Previous TB: Yes          | 2.81          | 0.90      | 0.99      | 0.96        | 1.06                 | 0.98         |
|                          | (1.19, 6.08)  | (0.81, 1.00) | (0.86, 1.13) | (0.83, 1.10) | (0.96, 1.16) | (0.93, 1.03) |

All models also adjusted for weight (kg), height (cm); total n = 1303 due to missing weight data.

** Only one person had both TB and wheeze or TB and phlegm or TB and dyspnoea, TB was excluded from these models.

### Table 3: Coefficient estimates (95% CI) for continuous spirometry outcomes FEV₁, FVC, FEV₁/FVC ratio (n=886)

| Variable                  | FEV₁         | FVC          | FEV₁/FVC |
|---------------------------|--------------|--------------|----------|
| Age (years)               | -0.02 (-0.02, -0.02) | -0.01 (-0.01, -0.01) | -0.28 (-0.31, -0.24) |
| Male                      | ref          | ref          | ref      |
| Female                    | -0.53 (-0.60, -0.45) | -0.70 (-0.78, -0.62) | 1.37 (0.18, 2.56) |
| Never smoked              | ref          | ref          | ref      |
| Ever smoked               | -0.09 (-0.16, -0.01) | -0.05 (-0.14, 0.04) | -1.76 (-2.99, -0.53) |
| Previous TB: No           | ref          | ref          | ref      |
| Previous TB: Yes          | -0.46 (-0.64, -0.28) | -0.36 (-0.56, -0.15) | -7.83 (-10.74, -4.91) |
| Years education           | 0 (0, 0.01)  | 0 (-0.01, 0.01) | 0.18 (0.05, 0.3) |

* All models also adjusted for weight (kg) and height (cm).
Table 4: OR (95% CI) for symptom outcomes estimated by multivariable logistic regression in participants with exposure measurements (n=985)

|                     | Cough | Phlegm** | Wheeze** | Dyspnoea** | Functional limitation | Any symptoms |
|---------------------|-------|----------|----------|------------|-----------------------|--------------|
| Ever smoked (ref: never smoked) | 1.72 (1.02, 2.91) | 0.99 (0.37, 2.53) | 0.35 (0.02, 2.32) | 2.62 (0.56, 11.24) | 0.78 (0.20, 2.47) | 1.67 (1.02, 2.71) |
| Previous TB (ref: no previous TB) | 2.87 (1.07, 6.87) | - | - | - | 3.00 (0.45, 11.74) | 2.47 (0.91, 6.07) |
| CO (log₁₀ ppm) | 1.29 (0.93, 1.77) | 1.50 (0.83, 2.54) | 2.12 (0.96, 4.16) | 1.27 (0.48, 2.88) | 1.45 (0.81, 2.43) | 1.46 (1.04, 2.05) |
| PM₂.₅ (log₁₀ µg/m³) | 1.02 (0.95, 1.13) | 0.96 (0.88, 1.11) | 1.00 (0.87, 1.38) | 1.11 (0.89, 1.67) | 0.99 (0.90, 1.16) | 1.02 (0.95, 1.11) |

All models adjusted for weight (kg), height (cm), age (yrs), sex (Male, Female) and years formal education.
** Only one person had both TB and wheeze or TB and phlegm or TB and dyspnoea, TB was excluded from these models.

Table 5: Coefficient estimates (95% CI) for continuous spirometry outcomes FEV₁, FVC, FEV₁/FVC ratio in participants with personal air pollution exposure measurements (n=886)

| Variable            | FEV₁         | FVC          | FEV₁/FVC        |
|---------------------|--------------|--------------|-----------------|
| Age (years)         | -0.02 (-0.02, -0.01) | -0.01 (-0.02, -0.01) | -0.28 (-0.35, -0.20) |
| Male                | ref          | ref          | ref             |
| Female              | -0.58 (-0.61, -0.44) | -0.70 (-0.79, -0.60) | 1.25 (-0.09, 2.56) |
| Never smoked        | ref          | ref          | ref             |
| Ever smoked         | -0.1 (-0.19, -0.02) | -0.07 (-0.16, 0.03) | -1.83 (-3.20, -0.45) |
| Previous TB: No     | ref          | ref          | ref             |
| Previous TB: Yes    | -0.32 (-0.52, -0.11) | -0.26 (-0.49, -0.02) | -6.16 (-9.48, -2.85) |
| Years education     | 0 (0, 0.01)  | 0 (-0.01, 0.01) | 0.15 (0.01, 0.29) |
| CO (log₁₀ ppm)      | 0.01 (-0.04, 0.06) | 0.01 (-0.04, 0.07) | 0.13 (-0.68, 0.94) |
| PM₂.₅ (log₁₀ µg/m³) | 0 (-0.02, 0.01) | 0 (-0.01, 0.01) | -0.11 (-0.29, 0.08) |

* All models also adjusted for weight (kg) and height (cm).
Table 6: CAPS ITT secondary trial analyses (n=424)

| Outcome                  | Intervention (n=227) | Control (n=197) | Intervention vs control Estimate (95% CI) | p-value |
|--------------------------|----------------------|-----------------|------------------------------------------|---------|
| Symptoms (n (%))         | 22 (9.7%)            | 26 (13.2%)      | 0.90 (0.45, 1.82)**                      | 0.87    |
| FEV₁ [med (IQR)]        | 2.81 (2.39, 3.26)    | 2.77 (2.40, 3.10)| 0.08 (-0.06, 0.22)                      | 0.26    |
| FVC [med (IQR)]         | 3.37 (2.88, 3.91)    | 3.31 (2.83, 3.86)| 0.04 (-0.13, 0.21)                      | 0.62    |
| Mean CO [med (IQR)]     | 1.13 (0.79, 1.90)    | 1.28 (0.82, 1.79)| 0.67 (-0.60, 1.96)                      | 0.30    |
| Mean PM₂.₅ [med (IQR)]  | 67.90 (44.72, 112.95)| 64.47 (40.73, 101.80)| -931.6 (-2073.6, 209.7)                 | 0.11    |

** OR (95% CI)
Figure 1: Participant recruitment flow diagram

Chikhwawa, rural study
Target population N = 62,207

Age and gender stratified random sampling
N = 3,000

Ineligible for inclusion or unable to locate
n = 1,519

Eligible for inclusion and consented to participate
N = 1,481

Contra-indication (medically unfit) = 193
Heart conditions = 38
Pregnancy = 24
Recent eye/chest surgery = 13
Active TB = 9
Pulse > 120 bpm = 3
Other = 106
Refused to do spirometry = 69
Unable to understand instructions = 11

Completed data collection & attempted spirometry
N = 1208

Unable to physically cooperate
n = 258

Acceptable spirometry
N = 886

Unacceptable spirometry
N = 64

Figure 1. Participant recruitment flow diagram.
Figure 2: Age stratified prevalence of respiratory symptoms

Figure 3: Scatter plot between personal exposure to PM$_{2.5}$ and CO

$R^2 = 0.113$
Online Data Supplement

Table E1: OR (95% CI) for chronic respiratory symptom outcomes estimated by multivariable logistic regression as shown in Table 2 but with the addition of a variable for completing or not completing spirometry

| Variable          | Cough     | Phlegm** | Wheezé** | Dyspnoea** | Functional limitation | Any symptoms |
|-------------------|-----------|----------|----------|------------|----------------------|--------------|
| **Age (years)**   | 1·01      | 1·00     | 1·02     | 1·01       | 1·00                 | 1·01         |
|                   | (0·99, 1·02) | (0·99, 1·05) | (0·99, 1·05) | (0·98, 1·04) | (0·97, 1·02) | (1·00, 1·02) |
| **Male**          | ref       | ref      | ref      | ref        | ref                  | ref          |
|                   | 0·77      | 1·02     | 0·97     | 3·08       | 1·18                 | 1·07         |
| **Female**        | (0·48, 1·25) | (0·42, 2·51) | (0·30, 3·28) | (0·88, 11·65) | (0·47, 3·11) | (0·69, 1·65) |
| **Never smoked**  | ref       | ref      | ref      | ref        | ref                  | ref          |
|                   | 1·57      | 1·37     | 0·77     | 1·85       | 0·65                 | 1·59         |
| **Ever smoked**   | (1·02, 2·41) | (0·58, 3·15) | (0·20, 2·47) | (0·51, 6·07) | (0·18, 1·93) | (1·05, 2·38) |
| **Previous TB**   |           |          |          |            |                      |              |
| **No**            | ref       |          |          | ref        | ref                  | ref          |
|                   | 2·84      |          |          | 2·64       | 2·52                 | 2·52         |
|                   | (1·21, 6·08) |          |          | (0·40, 9·94) | (1·05, 5·62) | (1·05, 5·62) |
| **Yes**           | 0·97      | 0·90     | 0·99     | 0·96       | 1·06                 | 0·98         |
|                   | (0·92, 1·02) | (0·81, 1·00) | (0·86, 1·13) | (0·83, 1·10) | (0·96, 1·16) | (0·93, 1·03) |
| **Years education** |          |          |          |            |                      |              |
| **Spiro complete**|           |          |          |            |                      |              |
| **No**            | ref       | ref      | ref      | ref        | ref                  | ref          |
|                   |          |          |          |            |                      |              |
| **Yes**           | 0·73      | 1·06     | 0·74     | 0·80       | 1·11                 | 0·82         |
|                   | (0·5, 1·06) | (0·51, 2·35) | (0·28, 2·02) | (0·30, 2·28) | (0·53, 2·52) | (0·58, 1·17) |

All models also adjusted for weight (kg), height (cm); ** Only one person had both TB and wheeze or TB and phlegm or TB and dyspnoea, TB was excluded from these models.